Ventilator Associated Pneumonia (VAP) Therapeutics Market
Pipeline Review, H2 2017
“Pharmaceutical and Healthcare disease pipeline guide Ventilator
Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides an
overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease)
pipeline landscape.”
Summary
Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline
Review, H2 2017, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease)
pipeline landscape.
Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical
ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia
(VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The
most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing
amounts of oxygen in the blood).
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review,
H2 2017, provides comprehensive information on the therapeutics under development for Ventilator
Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Browse Detail Report With TOC @ http://www.hexareports.com/report/ventilator-associated-
pneumonia-vap-pipeline-review-h2-2017
Follow Us: